Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

(S1609) DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

Principal Investigator: Puzanov, Igor

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

Principal Investigator: Twist, Clare J

Use of Trifluridine/tipiracil (TAS-102) and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and gastroesophageal junction (GEJ) adenocarcinoma

Principal Investigator: Mukherjee, Sarbajit

A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) after a Myeloablative Conditioning Regimen, with…

Principal Investigator: Odunsi, Adekunle O

(S1602) A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer

Principal Investigator: Li, Qiang J

Phase I Clinical Trial Assessing the Combination of Chemokine Modulation with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Principal Investigator: Gandhi, Shipra

A multinational, open-label, dose escalation Phase I Study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types

Principal Investigator: Odunsi, Adekunle O

A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Principal Investigator: Chen, Hongbin

RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy

Principal Investigator: Chen, Hongbin

A Phase II Study of Intensive Salvage Therapy Followed by Enasidenib for Patients with AML Harboring Mutations in IDH2 who have Failed or been Refractory to Frontline Therapy

Principal Investigator: Thota, Swapna

Randomized Phase 2 Study: Neoadjuvant conditioning of prostate cancer tumor microenvironment using a novel chemokine-modulating regimen

Principal Investigator: Chatta, Gurkamal S

A randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)

Principal Investigator: Griffiths, Elizabeth A

Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)

Principal Investigator: Przespolewski, Amanda C

EA9161: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Principal Investigator: Sundaram, Suchitra

EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

Principal Investigator: Singh, Anurag K

(COG #AGCT1532) Phase 3 Accelerated BEP Trial:A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Principal Investigator: Levine, Ellis G

(IS0-CC-007): A Randomized, Multicenter, Parallel-Group, Phase III Study To Compare The Efficacy Of Arfolitixorin Versus Leucovorin In Combination With 5 Fluorouracil, Oxaliplatin, And Bevacizumab In Patients With Advanced Colorectal Cancer

Principal Investigator: Mukherjee, Sarbajit

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum Based Regimen or Anti-PD-a/ PD-L1 Based Immunotherapy

Principal Investigator: George, Saby

Phase Ib/II Study of Enzalutamide with Venetoclax (ABT-199) in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Principal Investigator: Chatta, Gurkamal S

A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors (POD1UM-102)

Principal Investigator: Fountzilas, Christos

(CITN-14) Randomized Phase II study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma

Principal Investigator: Chatta, Gurkamal S

A Phase I Study of pevonedistat (MLN4924, TAK924) in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and non-Hodgkin lymphoma

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

(EA2165) A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Principal Investigator: Mukherjee, Sarbajit

A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

Principal Investigator: Fountzilas, Christos

A randomized phase II study to evaluate efficacy of TDM1with or without Palbociclib in the treatment of patients with metastatic HER2 positive breast cancer

Principal Investigator: Gandhi, Shipra